On July 28, LEADS BIOLABS-B fell 5.51% in regular trading, trading at HK$56.7/share with turnover of HK$360 million, extending the prior session's decline.

On the news front, the stock is facing sustained selling pressure following its one-year listing anniversary, which triggered an early shareholder lock-up expiry window. Kunming Pharmaceutical Group announced plans to fully liquidate its position, reducing up to 2,443,022 shares of LEADS BIOLABS via block trades or centralized bidding, involving approximately RMB 132 million. The move is aimed at strengthening its core business and optimizing asset structure. On the previous trading day, the stock plunged as much as 17% intraday, closing down 8.25%, indicating the unlock-related selling pressure has yet to be fully absorbed.

Notably, company co-founder and CEO Dr. Kang Xiaoqiang had voluntarily extended the lock-up period on his 7,874,617 H shares by six months to January 2027, signaling management confidence. However, Kunming Pharmaceutical's complete exit continues to weigh heavily on market sentiment in the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)